Martin Gomez

Martin Gomez is a partner in Goodwin’s Technology and Life Sciences Business Unit, specializing in intellectual property matters, and is a co-leader of the Firm’s MedTech and Artificial Intelligence practice groups. Martin focuses his practice on advising technology and life sciences companies of all sizes (including startups), and their investors, in corporate and especially intellectual property matters throughout the business life cycle, including new company formation, IP protection, fundraising, strategic transactions, and exits.

Martin is also a registered patent attorney. His practice includes intellectual property rights counseling, procurement, and enforcement, with significant experience in strategic patent portfolio development, transactional IP diligence, IP licensing, and patent and trade secret litigation. Martin also has special expertise with design patents, both in obtaining design patent protection for clients and in evaluating design patent portfolios in the transactional and litigation contexts.

Martin has a technical background in mechanical and biomedical engineering and has particular technical expertise in the areas of medical devices, laboratory testing / diagnostic equipment, digital health, and artificial intelligence. He also regularly advises clients in other technology areas, including robotics, clean energy, consumer products, and computer-implemented / software-based technologies. In addition to his practice before the U.S. Patent and Trademark Office, Martin also has experience litigating patent and trade secret disputes before the federal courts. 

Martin also maintains a robust pro bono practice. He assists local small businesses and entrepreneurs through Goodwin’s Neighborhood Business Initiative (NBI) and immigrant children through the Kids in Need of Defense (KIND) program. Martin was the recipient of the 2019 Robert B. Fraser Pro Bono Award, given annually by the firm to one associate and one partner that have made significant contributions to the firm’s pro bono efforts.

While attending law school, Martin served as Editor-in-Chief of IDEA: The Intellectual Property Law Review, an academic journal publishing articles related to patent, copyright, trademark, trade secret, unfair competition, and other law and technology issues from around the world.

Upon graduation from law school, Martin received the ALI/ABA Scholarship & Leadership Award, awarded by the faculty to the graduating law student who best represents scholarship and leadership.

• Co-Presenter, “How Do Intellectual Property Rights Apply to Generative AI Outputs,” April 25, 2023
• Co-Author, “U.S. Artificial Intelligence Regulations: Watch List for 2023,” April 12, 2023
• Co-Author, “Top 5 IP Considerations for Medtech Companies Transitioning To Data-enabled Product Solutions,” MedCity News, January 20, 2023
• Co-Author, “The Road Ahead: Examining the Outlook of Regulations for Self-Driving Cars,” July 23, 2021.
• Co-Author, “Five Tips For Life Sciences Companies to Protect Their AI Technologies,” February 25, 2021.

Martin has also published academically on the topic of U.S. patent law.

• Author, “Manufacturing Please Come Home: How AIA’s Prior User Right Could Be the American Economy’s Savior,” UC Davis Business Law Journal, Fall 2013